Terms: = Liver cancer AND DNAJB1, HSPF1, 3337, ENSG00000132002, P25685, Hdj1, Hsp40
69 results:
1. The Relationship between liver Volume, Clinicopathological Characteristics and Survival in Patients Undergoing Resection with Curative Intent for Non-Metastatic Colonic cancer.
McGovern J; Mackay C; Freireich R; Golder AM; Dolan RD; Horgan PG; Holroyd D; Jamieson NB; McMillan DC
Tomography; 2024 Feb; 10(3):349-359. PubMed ID: 38535769
[TBL] [Abstract] [Full Text] [Related]
2. dnajb1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
Ma RK; Tsai PY; Farghli AR; Shumway A; Kanke M; Gordan JD; Gujral TS; Vakili K; Nukaya M; Noetzli L; Ronnekleiv-Kelly S; Broom W; Barrow J; Sethupathy P
PLoS Genet; 2024 Mar; 20(3):e1011216. PubMed ID: 38512964
[TBL] [Abstract] [Full Text] [Related]
3. dnajb1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
Kirk AM; Crawford JC; Chou CH; Guy C; Pandey K; Kozlik T; Shah RK; Chung S; Nguyen P; Zhang X; Wang J; Bell M; Mettelman RC; Allen EK; Pogorelyy MV; Kim H; Minervina AA; Awad W; Bajracharya R; White T; Long D; Gordon B; Morrison M; Glazer ES; Murphy AJ; Jiang Y; Fitzpatrick EA; Yarchoan M; Sethupathy P; Croft NP; Purcell AW; Federico SM; Stewart E; Gottschalk S; Zamora AE; DeRenzo C; Strome SE; Thomas PG
Cell Rep Med; 2024 Mar; 5(3):101469. PubMed ID: 38508137
[TBL] [Abstract] [Full Text] [Related]
4. DNAJC8: a prognostic marker and potential therapeutic target for hepatocellular carcinoma.
Zhang Z; Ju M; Tang Z; He Z; Hua S
Front Immunol; 2023; 14():1289548. PubMed ID: 38274804
[TBL] [Abstract] [Full Text] [Related]
5. GalNAc-conjugated siRNA targeting the dnajb1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma.
Neumayer C; Ng D; Requena D; Jiang CS; Qureshi A; Vaughan R; Prakash TP; Revenko A; Simon SM
Mol Ther; 2024 Jan; 32(1):140-151. PubMed ID: 37980543
[TBL] [Abstract] [Full Text] [Related]
6. Discovery and Synthesis of a Naturally Derived Protein Kinase Inhibitor that Selectively Inhibits Distinct Classes of Serine/Threonine Kinases.
Du L; Wilson BAP; Li N; Shah R; Dalilian M; Wang D; Smith EA; Wamiru A; Goncharova EI; Zhang P; O'Keefe BR
J Nat Prod; 2023 Oct; 86(10):2283-2293. PubMed ID: 37843072
[TBL] [Abstract] [Full Text] [Related]
7. Identification of Long Non-Coding RNA Profiles and Potential Therapeutic Agents for Fibrolamellar Carcinoma Based on RNA-Sequencing Data.
Kim J; Kim Y; Lee B
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761849
[TBL] [Abstract] [Full Text] [Related]
8. Exploring the molecular pathogenesis, diagnosis and treatment of fibrolamellar hepatocellular carcinoma: A state of art review of the current literature.
Alshareefy Y; Shen CY; Prekash RJ
Pathol Res Pract; 2023 Aug; 248():154655. PubMed ID: 37429175
[TBL] [Abstract] [Full Text] [Related]
9. Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss.
Rüland L; Andreatta F; Massalini S; Chuva de Sousa Lopes S; Clevers H; Hendriks D; Artegiani B
Nat Commun; 2023 May; 14(1):2377. PubMed ID: 37137901
[TBL] [Abstract] [Full Text] [Related]
10. The oncogenic fusion protein dnajb1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS
Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754
[TBL] [Abstract] [Full Text] [Related]
11. Oncogenic Addiction of Fibrolamellar Hepatocellular Carcinoma to the Fusion Kinase dnajb1-PRKACA.
Neumayer C; Ng D; Jiang CS; Qureshi A; Lalazar G; Vaughan R; Simon SM
Clin Cancer Res; 2023 Jan; 29(1):271-278. PubMed ID: 36302174
[TBL] [Abstract] [Full Text] [Related]
12. β-catenin cancer-enhancing genomic regions axis is involved in the development of fibrolamellar hepatocellular carcinoma.
Gulati R; Johnston M; Rivas M; Cast A; Kumbaji M; Hanlon MA; Lee S; Zhou P; Lake C; Schepers E; Min KW; Yoon JH; Karns R; Reid LM; Lopez-Terrada D; Timchenko L; Parameswaran S; Weirauch MT; Ranganathan S; Bondoc A; Geller J; Tiao G; Shin S; Timchenko N
Hepatol Commun; 2022 Oct; 6(10):2950-2963. PubMed ID: 36000549
[TBL] [Abstract] [Full Text] [Related]
13. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.
Toyota A; Goto M; Miyamoto M; Nagashima Y; Iwasaki S; Komatsu T; Momose T; Yoshida K; Tsukada T; Matsufuji T; Ohno A; Suzuki M; Ubukata O; Kaneta Y
Biochem Biophys Res Commun; 2022 Sep; 621():157-161. PubMed ID: 35839742
[TBL] [Abstract] [Full Text] [Related]
14. The Use of Fluorescence
Weiel JJ; Forgo B; Sage J; Rangaswami A; Hazard FK
Ann Clin Lab Sci; 2022 May; 52(3):475-483. PubMed ID: 35777788
[TBL] [Abstract] [Full Text] [Related]
15. Successful liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Kang S; Magliocca J; Sellers M; Roccaro G; Zheng W; Pectasides M; Draper A; Guadagno J; El-Rayes B; Akce M
Oncol Res Treat; 2022; 45(7-8):430-437. PubMed ID: 35537414
[TBL] [Abstract] [Full Text] [Related]
16. Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
Francisco AB; Kanke M; Massa AP; Dinh TA; Sritharan R; Vakili K; Bardeesy N; Sethupathy P
JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35482409
[TBL] [Abstract] [Full Text] [Related]
17. A framework for fibrolamellar carcinoma research and clinical trials.
Dinh TA; Utria AF; Barry KC; Ma R; Abou-Alfa GK; Gordan JD; Jaffee EM; Scott JD; Zucman-Rossi J; O'Neill AF; Furth ME; Sethupathy P
Nat Rev Gastroenterol Hepatol; 2022 May; 19(5):328-342. PubMed ID: 35190728
[TBL] [Abstract] [Full Text] [Related]
18. dnajb1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling.
Kim SS; Kycia I; Karski M; Ma RK; Bordt EA; Kwan J; Karki A; Winter E; Aktas RG; Wu Y; Emili A; Bauer DE; Sethupathy P; Vakili K
PLoS One; 2022; 17(2):e0263829. PubMed ID: 35167623
[TBL] [Abstract] [Full Text] [Related]
19. Characteristics of false-positive lesions in evaluating colorectal liver metastases on gadoxetic acid-enhanced magnetic resonance imaging.
Yamada S; Kishi Y; Miyake M; Nara S; Esaki M; Shimada K
Surg Today; 2022 Aug; 52(8):1178-1184. PubMed ID: 35043218
[TBL] [Abstract] [Full Text] [Related]
20. Integrated Phosphoproteomics for Identifying Substrates of Human Protein Kinase A (
Karamafrooz A; Brennan J; Thomas DD; Parker LL
J Proteome Res; 2021 Oct; 20(10):4815-4830. PubMed ID: 34436901
[TBL] [Abstract] [Full Text] [Related]
[Next]
